anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a pillbug extract and an application thereof, relating to the field of pharmaceuticals. The pillbug extract has thrombolytic and anti-coagulant activities, and is prepared by adopting a method including the following steps: performing wet-process superfine grinding on pillbug, centrifuging, and collecting supernatant liquid to obtain the pillbug extract. The pillbug extract has thrombolytic and anti-coagulant activities, and is relatively mild in thrombolytic activity. According to the pillbug extract provided by the invention, a mode that fibrin is directly dissolved is not adopted, but a mode that plasminogen is activated to ensure that plasminogen is transformed into plasmin and thus fibrin is dissolved is adopted, so that the pillbug extract has relatively mild thrombolytic effects, the tendency of massive bleeding cannot be caused, and the risk of massive hemorrhage of tissues can be reduced. In addition, the pillbug extract provided by the invention is feasible and effective in preparation method, simple and convenient in technological process and easy to operate, and is suitable for industrial production. The pillbug extract provided by the invention can also be applied to the preparation of medicines for treating thrombotic diseases.
Participants will undergo standard photographs (2-D imaging) of their chest wall and torso, including the breasts, and complete a validated questionnaire (BREAST-QTM) to evaluate patient satisfaction, and quality of life, all standard of care. The 3D photographs, MRI, and US are routinely used in practice but will be performed for research purposes in this study.
The Programmed cell death protein 1 (PD1)/Programmed death-ligand 1 (PD-L1) axis is an important immune checkpoint for T cell activation that is used by tumors to evade the host immune response. Blocking signaling with the PD-L1 antibody MPDL3280A results in ongoing T cell activity and can induce durable tumor regression across numerous solid tumor types. PD-L1 is not only expressed by tumor cells but also by immune cells, activated vascular endothelial cells and in immune privileged sites such as the eye. An obstacle to using PD-L1 expression as predictive biomarker might be its potential heterogeneous expression and fast dynamics. For PD1/PD-L1 pathway inhibition PD-L1 tumor surface expression, positive in 40-100% of all melanoma patients and 35-95% of all non-small-cell lung cancer (NSCLC) patients, was proposed as a potential biomarker. In early clinical trials, PD-L1 expression has been associated with response to PD1/PD-L1 inhibition. However, other clinical trials reported response to PD1/PD-L1 checkpoint inhibitors in up to 47% of PD-L1-negative melanomas assessed by a single biopsy. In bladder cancer weak to strong PD-L1 expression has been reported in 30% of the patients, however also response in PD-L1-negative patients has been seen. For triple-negative breast cancer (TNBC) little is known, but early response data are also very promising.

Radio-labeling of MPDL3280A with the positron emission tomography (PET) radionuclide Zirconium-89 (89Zr) enables non-invasive imaging and quantification of PD-L1 distribution in cancer patients. By performing a 89Zr-MPDL3280A-PET scan prior to treatment with MPDL3280A, the uptake of the tracer in the primary and metastatic tumor lesions and normal organ distribution can be evaluated, as well as the use of a 89Zr-MPDL3280A-PET as a complementary tool for patient selection in the future. There is currently no information with regards to tumor saturation or inflammation induced by checkpoint inhibitors. This can be measured with SUV of 89Zr-MPDL3280A PET changes during a therapeutic dosing with MPDL3280A.
The depression user detection system of the present invention comprises a processing module, and a network module, a facial recognition module and a database module which are electrically connected to the processing module. The database module stores a plurality of facial expression data and a plurality of state data. The processing module receives a frame data from a first external device through the network module. When the facial recognition module judges that the frame data has a face data, the facial recognition module transmits the face data to the processing module. When the processing module judges that the face data is the same as one of the facial expression data, the processing module outputs the state data corresponding to the face data to a second external device through the network module. The doctor can grasp the depression degree of the user of the first external device in real time through the second external device so as to help the depression patients immediately. The database module further stores a travel distance research data and an observation time data. The observation time data includes a first unit time. The processing module receives a position data from the first external device through the network module. The processing module calculates a travel distance of the position data in the first unit time according to the observation time data. The processing module calculates the state data corresponding to the travel distance according to the travel distance research data. Further, the processing module outputs the state data to the second external device through the network module.
Squamous cell cancers of the head and neck (SCCHN) comprise 5% of all cancers, with 40,000 new cases diagnosed annually. Surgery followed by irradiation or irradiation alone has been the standard of care for locally advanced Stage III and IV patients. With this approach, fewer than 30% of patients achieve long-term remission, and most recur locoregionally. Neoadjuvant chemotherapy has been administered prior to definitive therapy with response rates ranging from 60-90%, with pathologic CR rates documented in 30-70% of clinical responders. However, large randomized trials have shown no improvement in overall survival. Because induction chemotherapy alone does not appear to improve long-term disease free survival in advanced head and neck cancers, concomitant chemotherapy and radiation has been pursued in patients with locally advanced head and neck cancers. The concept of synergy between radiation and chemotherapy is well established in vitro. Various schedules of radiation and chemotherapy have been utilized including weekly chemotherapy during radiation, chemotherapy given every three weeks during radiation and alternating chemotherapy and radiation.

One novel approach to capitalizes on the synergy between radiation and chemotherapy is the use of low doses fractionated radiation (LDFRT) as a chemotherapy enhancer. In vitro data suggests that LDFRT enhances the response of both p53 wild type and p53 mutant cancer cell lines to chemotherapy. Not only was the cell death fraction increased, but there was no development of radioresistance in the cell lines studies when low doses of radiation were utilized. This strategy was translated into a clinical trial using four 80-cGy fractions of radiation with Carboplatin and Paclitaxel. Preliminary results have produced an impressive 85% response rate and this neoadjuvant regimen was safe and easy to deliver in patients with locally advanced SCCHN patients. In recently published work by Belani, a regimen using Carboplatin every four weeks combined with weekly Paclitaxel improved response rates in non-small cell lung cancer. The delivery of chemotherapy on a weekly schedule would be of particular benefit when adding LDFRT, because tumor cells could be exposed to LDFRT on multiple occasions per cycle of induction therapy, without the theoretic development of radioresistance. We propose to expand our understanding of LDFRT and chemotherapy by using two cycles of Paclitaxel and Carboplatin in a modification of the Belani regimen, plus LDFRT as induction therapy prior to definitive treatment (surgery or radiation). It is hoped that using LDFRT as a chemoenhancer will further increase the response rate seen with induction therapy in this population of patients.
Left atrial appendage (LAA) closure can prevent stroke in high-risk patients with atrial fibrillation.A bioabsorbable LAA occluder made of degradable polymer materials, such as polydioxanone (PDO) and poly-L-lactic acid (PLA), and nitinol wire was used. Occluders were successfully implanted in 18 Chinese rural dogs, 2 of which died within 48 hours after operation due to pericardial tamponade and hemorrhage, respectively. Follow-up observation was performed after transcatheter LAA closure. New tissue was found on the surface of the occluder 2 months after operation. No adjacent structures such as the mitral valve and the left superior pulmonary vein were affected by the occluder discs. Hematoxylin and eosin (HE) staining was performed at 3 months after operation, which showed intact intimal structure on the occluder surface, and unabsorbed PDO and PLA were observed. Scanning electron microscopy showed irregular arrangement of endothelial cells. New endothelial tissue was observed to completely cover the occluder at 6 months after operation. Most PDOs were replaced by fibrous connective tissue, and scanning electron microscopy showed regularly arranged endothelial cells. Pathological examination at 12 months showed only a small remnant of PDO. The gross specimens of the liver, spleen, and kidneys and pathological examination did not indicate thromboembolism.The bioabsorbable LAA occluder made of PDO, PLA, and nitinol wire was safe and effective for the occlusion of LAA in dogs. The surface of the occluder was endothelialized half a year after operation. The absorbable materials of the occluder were degraded after 1 year.
The invention relates to the field of genetic engineering or biotechnology, and particularly discloses a preparation method and application of a fusion antibacterial peptide MPX/BSN-37, a recombinant vector, a recombinant cell strain or a crude extract, wherein the amino acid sequence of the fusion antibacterial peptide MPX/BSN-37 is shown as SEQ ID NO.1, and the nucleotide sequence is shown as SEQ ID NO. 2. The invention also provides recombinant vectors and recombinant cell lines comprising SEQ ID NO. 2. According to the invention, two antibacterial peptides MPX and BSN-37 are connected in series, fusion expression is carried out by eukaryotic Vero cells, the optimal concentration of exogenous plasmids is optimized, the stability of AMPs is improved, and the problem that AMPs are easy to degrade is solved. And finally transferring the recombinant plasmid into Vero cells through liposome transfection, crushing the cells, and performing freeze centrifugation treatment to prepare the crude antibacterial peptide. The crude extract can be used as feed additive to remarkably improve animal immunity, improve intestinal tract immunity index to a certain extent, and reduce morbidity.
The present invention provides methods and compositions for the stabilization of oxidase enzymes during storage. In some preferred embodiments, the oxidase is a component of liquid detergent compositions. In some particularly preferred embodiments, the oxidase is stabilized by the addition of a reversible inhibitor of the oxidase to a liquid detergent. In some particularly preferred embodiments, the oxidase is stabilized with bisulfite. In further preferred embodiments, the use of a reversible inhibitor also prevents premature generation of peroxide during storage of liquid detergent. In additional embodiments, liquid detergent formulations comprised of oxidase enzyme, its substrate, and its reversible inhibitor produce active oxygen species (peroxide) upon dilution of the liquid detergent in laundry wash liquor.
BACKGROUND: We aim to compare and assess the surgical parameters and follow-up information of one-hole split endoscopic discectomy (OSE) and microendoscopic discectomy (MED) in the treatment of LDH.
METHODS: This study included 154 patients with degenerative lumbar disk disease. Sixty-eight patients underwent OSE and 86 patients MED. The VAS score for lower back and lower limb radiation pain, ODI score, modified MacNab score, estimated blood loss (EBL), length of the incision, amount of C-reactive protein, and recurrence and complication rates were examined as indicators for clinical outcomes and adverse events.
RESULTS: After surgery, the VAS and ODI scores in the two groups significantly decreased. On the third day after surgery, the VAS and ODI scores of the OSE group were significantly better than those of the MED group. The VAS and ODI scores preoperatively and at 1 month, 3 months, 6 months, and 12 months following the procedure did not substantially vary between the two groups. There was less EBL and a shorter incision with OSE than with MED. There was no significant difference in the rate of complications between the two groups.
CONCLUSION: Compared with MED, OSE is a new alternative option for LDH that can achieve similar and satisfactory clinical outcomes. Furthermore, OSE has many advantages, including less EBL and a smaller incision. Further clinical studies are needed to confirm the effectiveness of OSE.
PURPOSE: A sustained-release safety sheet containing natural medicine for prevention and treatment of infections and a manufacturing method thereof are provided to prevent tolerance against antibiotics and environmental contamination and to release the medicine constantly. CONSTITUTION: A sustained-release safety sheet containing natural medicine for prevention and treatment of infections comprises an Olibanum solution in which Olibanum is dissolved, a natural medicine mixture, zeolite, gelatin and water. The natural medicine mixture is manufactured by mixing the natural medicine in which Galla Rhois is included with distilled water and hot water extracting thereof. The safety seat is manufactured by locating the raw material liquid on predetermined shaped sheet and drying thereof. A manufacturing method of the sustained-release safety seat comprises the following steps: a first process of dissolving the predetermined amount of olibanum in the distilled water, and mixing with gelatin; a second process of mixing 10 weight% of the natural medicine with 90 weight% of the distilled water and heating at 100-120 deg. Celsius for 6-10 hours and hot water extracting thereof in order for the active ingredient to be extracted; a third process of putting the natural medicine mixture manufactured in the second process and fibers into the liquid manufactured in the first process and mixing thereof; a fourth process of putting zeolite into a liquid manufactured in the third process and manufacturing a sheet material liquid by mixing thereof; and a fifth process of pouring the manufactured sheet material liquid into a predetermined shaped tray and natural drying the sheet for 3-5 days.
Whole-genome duplication (WGD), or polyploidization, is a major contributor to biodiversity. However, the establishment and survival of WGDs are often considered to be stochastic, since elucidating the processes of WGD establishment remains challenging. In the current study, we explored the processes leading to polyploidy establishment in snow carp (Cyprinidae: Schizothoracinae), a predominant component of the ichthyofauna of the Tibetan Plateau and its surrounding areas. Using large-scale genomic data from isoform sequencing, we analyzed ohnolog genealogies and divergence in hundreds to thousands of gene families across major snow carp lineages. Our findings demonstrated that independent autopolyploidization subsequent to speciation was prevalent, while autopolyploidization followed by speciation also occurred in the diversification of snow carp. This was further supported by matrilineal divergence and drainage evolution evidence. Contrary to the long-standing hypothesis that ancient polyploidization preceded the diversification of snow carp, we determined that polyploidy in extant snow carp was established by recurrent autopolyploidization events during the Pleistocene. These findings indicate that the diversification of extant snow carp resembles a coordinated duet: first, the uplift of the Tibetan Plateau orchestrated the biogeography and diversification of their diploid progenitors; then, the extensive Pliocene-Pleistocene climate changes acted as relay runners, further fueling diversification through recurrent autopolyploidization. Overall, this study not only reveals a hitherto unrecognized recent WGD lineage in vertebrates but also advances current understanding of WGD processes, emphasizing that WGD establishment is a nonstochastic event, emerging from numerous adaptations to environmental challenges and recurring throughout evolutionary history rather than merely in plants.
Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months.
Since inflammatory mediators play a crucial role in the pathophysiology of sepsis so anti-inflammatory treatment, Montelukast, could be a beneficial therapy. The investigators will conduct this pilot, open-labeled, randomized controlled intervention trial on 40 newborns admitted to NICU. The study will include late preterm infants with gestational age (34 weeks to less than 37 weeks) with clinical evidence of sepsis. The study included an intervention group (n=20) that will receive oral Montelukast for 10 days with antibiotics in addition to the conventional antibiotic therapy regimen according to NICU policy while the control group (n=20) will receive antibiotics in addition to the conventional antibiotic therapy regimen according to NICU policy. After obtaining a fully informed written consent from the neonate's parents or guardians, patients will be recruited and group allocated in the study by random pick up of closed opaque sealed envelopes. Patients will be observed clinically and by laboratory investigations along the duration of hospital admission through a structured collection sheet. Demographic data, cause of admission, clinical data (vital signs, activity, feeding intolerance, respiratory symptoms, duration of oxygen support, use of inotropes) will be recorded. Blood sampling will be performed twice in both groups, on admission, and 10 days after treatment. The following investigations will be carried out: complete blood picture, C-reactive protein (CRP), tumor necrosis factor-alpha (TNF alpha), blood culture, Serum creatinine, Liver enzymes, and INR. A lumbar puncture will be performed when the treating physicians suspect meningitis. Patients in both groups will be observed along the duration of hospital admission to detect the outcome.

Patients in the intervention group, receiving Montelukast sodium (Singulair), will be given at a dose according to body weight (1.5 kg to 2 kg, will be given 1.5 mg; greater than 2 kg, will be given 2 mg). This dose was previously prescribed and given to preterm neonates suffered from bronchopulmonary dysplasia by Kim et al. (2015). Four mg of the drug will be dissolved in four ml milk and 1.5 - 2 ml milk only will be given once daily at 9 pm via an orogastric tube or by oral administration for 10 days. Along the period of NICU admission, patients receiving Montelukast will be closely observed for the development of any of its side effects that including "diarrhea, colic, vomiting, fever or cough" (Adelsberg et al., 2005).
All patients in the GLN group received an oral maltodextrin supplement, similar in shape and texture as GLN supplement. The total placebo given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
The utility model relates to a face mask for preventing and treating allergic asthma. The face mask comprises an outermost layer and an innermost layer and is characterized in that the face mask is also provided with a traditional Chinese medicine bag layer which is sewn up between the outermost layer and the innermost layer. The face mask has simple structure, is convenient to use, adopts a pure Chinese medicine preparation, is harmless to human bodies and has very good prevention and treatment effect on the allergic asthma. The face mask is lower in cost, can be used more than once and takes effect after being worn for five minutes. A dose of medicine can be used for about 3 moths. When the face mask is not in use, the face mask is timely placed in a plastic bag to prevent the medicine taste from scattering and the medicine from losing efficacy.
The present invention relates to machine learning capable of extracting unstructured clinical data. The method may include receiving a message including unstructured clinical data from one or more data systems. A machine learning model may be applied to identify a first entity and a second entity present in unstructured clinical data. The first entity and the second entity may occupy a same row or a same column of consecutive rows of unstructured clinical data. The machine learning model may be trained to determine, based at least on unstructured clinical data including the first entity, that the second entity is the entity that is most likely to occupy a next position in a same row or a next row of a same column of unstructured clinical data. Clinically significant data can be extracted from the structured clinical data. Based at least on the clinically significant data, at least one medical device may be controlled to perform one or more tasks.
Ciprofloxacin is a commonly used antibiotic commonly used for prevention of UTI after catheterization. It belongs to a class of antibiotics known as the fluoroquinolones. Dosage will be ciprofloxacin 500 mg, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
Herein is disclosed amphiphilic small molecules with different hydrophobic and hydrophilic fragments that show high binding affinity to both Aβ plaques and oligomers, and selectively binding Aβ oligomers. These amphiphilic compounds can also label the Aβ species in the brain sections of transgenic AD mice, as shown by immunostaining with an Aβ antibody. Certain amphiphilic compounds were found to alleviate the Cu 2+ -Aβ induced toxicity in cell viability assays. Additionally, two compounds, ZY-15-MT and ZY-15-OMe, were found to disrupt the interactions between Aβ oligomers and human neuroblastoma SH-SY5Y cell membranes. These studies show compounds with amphiphilic properties that target Aβ oligomers and modulate the Aβ oligomer-cell membrane interactions can be effective as small molecule AD therapeutics. Also, the disclosed amphiphilic dicyanomethylene compounds that can emit in the near-infrared region and chelate copper can be used as early diagnostic agents for AD.